Business Wire

Parse Biosciences Launches Evercode Whole Transcriptome Version 3, Boosting Usability and Performance

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced a significant update to the company’s flagship Evercode™ ...
PharmiWeb

Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

SEATTLE, Wash. & VENLO, the Netherlands--(BUSINESS WIRE)--$QGEN #QIAGEN--Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the ...
Business Wire

Parse Biosciences Raises $41.5M Series B Round to Scale Single-Cell Sequencing Products and Expand Product Portfolio

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a company dedicated to providing scalable single-cell sequencing solutions, today announced $41.5M in Series B funding co-led by Marshall Wace and Janus ...
Yahoo Finance

Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

SEATTLE, Wash. & VENLO, the Netherlands, February 19, 2026--(BUSINESS WIRE)--Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and ...
Morningstar

Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

New chemistry reduces barriers to scaling single-cell studies across research settings Launch planned for March 2026, available across Evercode Whole Transcriptome product line Parse Biosciences, a ...